Delving into the Latest Updates on Lobaplatin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors), DNA alkylating agents

Therapeutic Areas

NeoplasmsHemic and Lymphatic DiseasesRespiratory Diseases+ [3]

Active Indication

Breast CancerLeukemiaSmall Cell Lung Cancer+ [2]

Inactive Indication-

Originator Organization-

Active Organization

Hainan Chang'an International Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC9H18N2O3Pt

InChIKeyRLXPIABKJFUYFG-UHFFFAOYSA-M

CAS Registry135558-11-1

BACKGROUNDThe therapeutic benefit of concurrent chemoradiotherapy (CCRT) in elderly nasopharyngeal carcinoma (NPC) patients remains controversial. This study aimed to investigate the efficacy and toxicity of lobaplatin-based CCRT in elderly patients with NPC.METHODSWe included stage II-IVA NPC patients aged ≥65 years who received lobaplatin concomitant with intensity-modulated radiation therapy (IMRT) between March 2019 and January 2023. Objective response rates and treatment-related toxicity were assessed. Kaplan-Meier's analysis was performed to calculate survival rates.RESULTSA total of 29 patients were included with a median age of 67 years. There were 19 patients (65.5%) who had comorbidities. All patients had serum EBV-DNA detective before treatment; the median EBV-DNA load was 236 IU/mL. There were 25 (86.2%) patients treated with induction chemotherapy, and the overall response rate was 92.0%. All patients received IMRT and concurrent chemotherapy with lobaplatin. During the CCRT, the most common adverse effect was haematological toxicity. Three patients (10.3%) had grade 3 leucopenia, three patients (10.3%) had grade 3 neutropenia, and eight patients (27.6%) had grade 3-4 thrombocytopenia. The rate of grade 3 mucositis was 34.5%. No patients had liver and kidney dysfunction. The median weight loss was 4 kg during CCRT. After three months of CCRT, the total response rate was 100%. EBV-DNA was not detected in any patients. The median follow-up was 32.1 months. The 3-year locoregional recurrence-free survival, distant metastasis-free survival, progression-free survival and overall survival were 95.8%, 85.7%, 82.5% and 100%, respectively.CONCLUSIONSLobaplatin-based CCRT is safe and feasible for elderly NPC patients, with satisfactory short-term survival outcomes and acceptable toxicities. A phase 2 trial is ongoing to investigate the role of lobaplatin-based CCRT on long-term survival and treatment toxicities for this population.

01 Dec 2024·BMJ Open

Thoracic perfusion of antiangiogenic agents combined with chemotherapy for treating malignant pleural effusion in non-small cell lung cancer: a network meta-analysis

Review

Author: Zhu, Xiaohua ; Jiang, Liming ; Cui, Yingying ; Xu, Yan ; Si, Wei ; Yu, Yinan

ObjectivesDifferent intrathoracic perfusion therapeutic regimens are available for non-small cell lung cancer with malignant pleural effusion (MPE). Antiangiogenic agents are often used to control MPE, and the results are satisfactory. Here, we performed a network meta-analysis to reveal optimal combinations of antiangiogenic agents and chemical agents and assess their effectiveness and safety.DesignSystematic review and network meta-analysis.Data sourcesPubMed/Medline, Embase, Cochrane, Web of Science, Wanfang, VIP Database and Chinese National Knowledge Infrastructure were searched from inception to May 2023. Eligible studies were randomised controlled trials that reported on curative effect of MPE.Data extraction and synthesisThe Cochrane Collaboration tool was used to assess risk of bias. The consistency was evaluated by examining the agreement between direct and indirect effects. Network meta-analysis was performed and the ranking probabilities of being at each possible rank for each intervention were estimated. Comparison-adjusted funnel plots were obtained to assess publication bias.ResultsA total of 46 studies were included in the analysis. Among them, we included a total of seven interventions. A total of 3026 patients participated in this analysis. According to the results of the network meta-analysis, some antiangiogenic agents combined with chemotherapy regimens improved objective response rate (ORR) and disease control rate (DCR) and quality of life (QOL). The rank probabilities suggested that in terms of ORR, DCR and QOL, Endostar plus lobaplatin was the first-ranked intervention.ConclusionAdministration of antiangiogenic agents plus chemical agents significantly improved the clinical response and QOL. In addition, Endostar plus lobaplatin was the most effective combination.PROSPERO registration numberCRD42021284786.

01 Nov 2024·Minerva Surgery

Analysis of clinical efficacy of intraperitoneal chemotherapy with lobaplatin for colorectal cancer

Article

Author: Wang, Ximo ; Yu, Xiangyang ; Zheng, Yang ; Wang, Tao ; Fei, Jiandong ; Wang, Honglei

100 Deals associated with Lobaplatin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XA	DB13049

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Breast Cancer	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-
Leukemia	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-
Small Cell Lung Cancer	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ovarian Epithelial Carcinoma	Phase 2	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	30 May 2018
Platinum-sensitive epithelial ovarian cancer	Phase 2	CN	Hainan Chang'an International Pharmaceutical Co. Ltd.	30 May 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06198465 (ESMO_IO2024) Manual	Phase 2	Gastroesophageal junction adenocarcinoma Neoadjuvant	15	Adebrelimab + nab-paclitaxel + lobaplatin + S-1	(fjvwjtveaq) = sjevebhgjn vvndkhgblu (thsqhjwlvn ) View more	Positive	12 Dec 2024
ChiCTR2100043027 (neoALTAL, ESMO 12023 \| ESMO 22023) Manual	Phase 2	Triple Negative Breast Cancer Neoadjuvant	45	Anlotinib + docetaxel+nab-paclitaxel + lobaplatin	(jtcuouvwab) = rpzzetmzsz gljuliipyz (nltmxqlbvc, 42.2 - 72.3) View more	Positive	21 Oct 2023
				Anlotinib + docetaxel+nab-paclitaxel + lobaplatin (IM subtype)	(jtcuouvwab) = osnuodijcm gljuliipyz (nltmxqlbvc )
ASCO2023	Not Applicable	Nasopharyngeal Carcinoma Neoadjuvant	44	Tislelizumab and GP regimen	egjxewfmpz(qnemmsgfzb) = Grade 3-4 irAEs were rash(2) and hypothyroidism(1) ukakrxvtwx (ssxssgrcxt )	Positive	31 May 2023
				Chemoradiotherapy including IMRT, lobaplatin and nimotuzumab
ChiCTR2100043027 (SWH-B006 (neoALTALL), SABCS2023)	Phase 2	Triple Negative Breast Cancer Neoadjuvant Ki-67 \| TP53 \| MYC ... View more	24	Anlotinib + Taxanes + Lobaplatin	jmqermwgzy(ayvtkmatpl) = ekddjtbfsv binywobpae (vofkcvzgrh, 36.6% - 77.9) View more	Positive	01 Mar 2023
Pubmed Manual	Not Applicable	Non-squamous non-small cell lung cancer Second line	126	Lobaplatin+Albumin-Bound Paclitaxel+Bevacizumab	(wdqeetjlbi) = izdxakiyau uykfqbbkft (oumrazmuxo, 5.86 - 6.56) View more	Positive	26 Jun 2022
				Lobaplatin+Albumin-Bound Paclitaxel	(wdqeetjlbi) = stltxftlxi uykfqbbkft (oumrazmuxo, 4.956 - 5.191) View more
NCT03057106 (CCTG BR34 \| CCTG BR.34, CTgov)	Phase 2	Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	301	Tremelimumab+Durvalumab (Durvalumab and Tremelimumab)	(uziubfjpyj) = iofsdrpeda kvpsnjhjds (bgxofxgmxv, vkaguqvztz - nfkhvnvhgr) View more	-	09 Feb 2022
				Tremelimumab+Lobaplatin+Cisplatin,+Durvalumab+Nedaplatin (Platinum Based Chemotherapy + Durvalumab + Tremelimumab)	(uziubfjpyj) = gdjytaunag kvpsnjhjds (bgxofxgmxv, yohicmiucx - ukhbzslpfu) View more
NCT03413436 (Pubmed \| Front Oncol)	Phase 4	Esophageal Carcinoma Adjuvant	733	Lobaplatin plus docetaxel	cjjzfsyscb(eifyywzlti) = pggmwxfqgm ogolnaxkja (cfefhdrwmw ) View more	-	01 Jan 2021
				Cisplatin plus docetaxel	cjjzfsyscb(eifyywzlti) = cpocunbpnm ogolnaxkja (cfefhdrwmw ) View more
CSCO2020	Not Applicable	Uterine Cervical Cancer	90	白蛋白紫杉醇联合洛铂经介入栓塞给药化疗	blkekvnjjp(ysvfuymxfd) = mqhxrselop ksbyhdemwj (qekcxfkxzj )	Positive	19 Sep 2020
NCT03188497 (Pubmed \| Transl Oncol)	Phase 1	Nasopharyngeal Carcinoma	17	Lobaplatin 25-50 mg/m2	(grbzzpozfj) = hymlhkiynm wetespydml (qhfjdfuftm )	-	01 Aug 2018
ChiCTR-TRC-10001047 (ASCO2014)	Phase 3	Extensive stage Small Cell Lung Cancer First line	234	Lobaplatin/Etoposide	(zmwjxcgxoq) = txpiufyrbc pvjldqzqwh (umpbhjtsnd ) View more	-	20 May 2014
				Cisplatin/Etoposide	(zmwjxcgxoq) = dlujmvykva pvjldqzqwh (umpbhjtsnd ) View more